Previous close | 0.9580 |
Open | 0.9720 |
Bid | 0.9855 x 800 |
Ask | 1.0100 x 1400 |
Day's range | 0.9580 - 1.0100 |
52-week range | 0.8500 - 8.8700 |
Volume | |
Avg. volume | 3,485,715 |
Market cap | 104.854M |
Beta (5Y monthly) | 0.13 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.4900 |
Earnings date | 30 Oct 2023 - 03 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 11.13 |
Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL WASHINGTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The American College of Cardiology, through a strategic collaboration with Amgen and Esperion, is launching a new quality improvement campaign, “Driving Urgency in LDL Screening,” to increase the rate of diagnostic LDL screening in patients without a prior cardiac event as well as those with known cardiovascular d
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig, President and Chief Executive Officer, will participate in a corporate presentation on Monday, September 11, 2023 at 3:00 PM ET. The Esperion management team will also host investor meetings that same day. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investo